Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.23.3
Stockholders' Equity - Additional Information (Details) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 28, 2023
May 25, 2023
Apr. 27, 2023
Aug. 03, 2022
Aug. 01, 2022
May 31, 2022
Jan. 31, 2022
Feb. 28, 2022
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 01, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock, shares authorized 70,000,000         70,000,000       70,000,000         70,000,000     70,000,000  
Preferred stock, shares authorized 30,000,000         30,000,000       30,000,000         30,000,000     30,000,000  
Common stock, par value $ 0.0001                 $ 0.0001         $ 0.0001     $ 0.0001  
Common stock, shares issued 13,761,123                 13,761,123         13,761,123     10,955,904  
Common stock per share                 $ 9                    
Gross proceeds from sale of common stock         $ 9,093,830   $ 99,999   $ 2,373,561             $ 2,473,560      
Warrants exercise price, per share           $ 6.25                          
Transaction costs             $ 0   $ 0                    
Deemed dividend on warrant modification                               (450,578)      
Warrants exercised, shares             394,501                        
Cashless exercise at fair market value per share             $ 9                        
Issuance of common shares upon cashless exercise of warrants, shares             315,601                        
Stock options outstanding 7,860,736                 7,860,736         7,860,736     6,545,628  
Fair value assumptions, contractual term                             7 years        
Exercise price percentage                             110.00%        
Percentage of shares granted                             10.00%        
Warrants and rights exercisable period           Jan. 23, 2023                          
Class of warrant or right date from which warrants or rights expire           Jul. 27, 2027                          
Warrants $ 103,407                 $ 103,407         $ 103,407     $ 245,341  
Gain on remeasurement of warrant liability                   $ (18,193)   $ (128,030)     (141,934) $ (128,030)      
Share Repurchase Program                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock, par value   $ 0.0001                                  
Share repurchase program expiration period   2024-09                                  
Shares repurchased 0                                    
Black-Sholes Method                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Risk free interest rate         2.82%                            
Volatility rate         77.50%                            
Fair value assumptions, contractual term         5 years                            
Warrants         $ 343,735                            
Gain on remeasurement of warrant liability                             $ 141,934        
January 1 to January 26, 2022                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock, par value                       $ 8.87       $ 8.87      
January 27 to May 31, 2022                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Sale of common stock, price per share $ 9                 $ 9         $ 9        
June 1 to June 30, 2022                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Sale of common stock, price per share $ 5                 $ 5         $ 5        
Maximum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Fair value assumptions, contractual term                             10 years        
Warrants to purchase aggregate of common stock           100,000                          
Maximum | Share Repurchase Program                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Share repurchase authorized amount   $ 800,000                                  
2018 Stock Option Plan                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock reserved for issuance 0                 0         0        
Stock options outstanding 1,924,500                 1,924,500         1,924,500        
Amended and Restated 2020 Equity Incentive Plan                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock reserved for issuance 0                 0         0        
Stock options outstanding 3,935,000                 3,935,000         3,935,000        
2021 Equity Incentive Plan                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock reserved for issuance 1,912,548         1,909,518       1,912,548         1,912,548       1,956,993
Stock options outstanding 2,001,236                 2,001,236         2,001,236        
Percentage of increase in stock outstanding fully diluted     10.00%                                
IPO                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock, shares issued           219,872                          
Number of common stock sold           2,000,000                          
Issuance of common shares value           $ 1,099,360           $ 8,750,095              
Common stock per share           $ 5     $ 5                    
Gross proceeds from common stock           $ 10,000,000                          
Number of warrants exercise           20,520                          
Warrants exercise price, per share           $ 5                          
Overallotment Option                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Number of common stock sold         300,000                            
Common stock per share         $ 5                            
Gross proceeds from common stock         $ 1,500,000                            
Overallotment Option | Maximum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Class of warrant or right additional purchase aggregate of common stock         15,000                            
Follow-on Offering                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Issuance of common shares value                     $ 4,156,859                
Warrants exercise price, per share           $ 2.81                          
Risk free interest rate           4.09%                          
Volatility rate           86.30%                          
Fair value assumptions, contractual term           5 years                          
Warrants and rights exercisable period           Oct. 24, 2023                          
Class of warrant or right date from which warrants or rights expire           Apr. 24, 2028                          
Class of warrant or right additional purchase aggregate of common stock           241,009                          
Follow-on Offering | Maximum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Warrants to purchase aggregate of common stock           127,775                          
At-the-Market Equity Offering                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Common stock, par value                                 $ 0.0001    
Common Stock                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Number of common stock sold             11,111   263,729                    
Sale of common stock, price per share             $ 9   $ 9                    
Issuance of common shares upon exercise of warrants, Shares             153,000 61,111         468,601 61,111          
Proceeds from issuance of common stock upon exercise of warrants             $ 275,400 $ 110,000                      
Common Stock | IPO                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Number of common stock sold                       2,300,000              
Issuance of common shares value                       $ 230              
Common Stock | Follow-on Offering                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Number of common stock sold                     2,555,500                
Issuance of common shares value                     $ 256                
Common Stock | At-the-Market Equity Offering | Maximum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Aggregate offering price                                 $ 7,000,000    
Founder                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Stock compensation expense                               $ 52,500      
Restricted Stock Awards                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Stock compensation expense                             $ 682,962        
Shares granted                             248,969        
Unvested shares 0                 0         0        
Restricted Stock Awards | Founder                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Shares granted                               29,168      
MAIA Stock Warrants                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Warrant modification, value               $ 144,497                      
Deemed dividend on warrant modification                               $ 450,578      
Stock Options                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Weighted-average grant date fair value                             $ 3.12 $ 5.97      
Unrecognized compensation $ 3,995,070                 $ 3,995,070         $ 3,995,070        
Unrecognized compensation expense, recognized period                             2 years 10 months 24 days        
Stock Options | Maximum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Fair value assumptions, contractual term                             6 years 3 months 6 years 3 months      
Stock Options | Minimum                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Fair value assumptions, contractual term                             5 years 5 years      
ThinkEquity LLC | Follow-on Offering                                      
Subsidiary or Equity Method Investee [Line Items]                                      
Number of common stock sold       2,555,500                              
Common stock per share       $ 2.25                              
Gross proceeds from common stock       $ 4,398,000